Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLiabilities from Discontinued OperationsLiabilities from Discontinued OperationsLong-Term Deferred TaxLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNon-Current Deferred Tax LiabilityOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Sanofi (SNY) Receivables (2016 - 2025)

Sanofi's Receivables history spans 17 years, with the latest figure at $11.5 billion for Q4 2025.

  • On a quarterly basis, Receivables rose 18.09% to $11.5 billion in Q4 2025 year-over-year; TTM through Dec 2025 was $11.5 billion, a 18.09% increase, with the full-year FY2025 number at $11.5 billion, up 18.09% from a year prior.
  • Receivables hit $11.5 billion in Q4 2025 for Sanofi, up from $8.8 billion in the prior quarter.
  • Over the last five years, Receivables for SNY hit a ceiling of $11.5 billion in Q4 2025 and a floor of $1.4 billion in Q4 2021.
  • Historically, Receivables has averaged $8.6 billion across 5 years, with a median of $9.0 billion in 2022.
  • Biggest five-year swings in Receivables: tumbled 84.08% in 2021 and later skyrocketed 524.08% in 2022.
  • Tracing SNY's Receivables over 5 years: stood at $1.4 billion in 2021, then skyrocketed by 524.08% to $8.9 billion in 2022, then rose by 19.04% to $10.6 billion in 2023, then fell by 8.3% to $9.7 billion in 2024, then rose by 18.09% to $11.5 billion in 2025.
  • Business Quant data shows Receivables for SNY at $11.5 billion in Q4 2025, $8.8 billion in Q2 2025, and $9.7 billion in Q4 2024.